RxDoctor Payments Data

Taku Kambayashi, MD

Blood Banking & Transfusion Medicine · Philadelphia, PANPI 1467519447

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $50,358 of the $51,590 with a category attached, or 97.6%. Grifols, S.A. accounts for 95.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $49,093 and has fallen 99.8% since, to $117 in 2023.

$51,590in general payments, 2019–2025

Across 4 payments — averaging $12,898 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Grifols, S.A.$49K
  • E.r. Squibb & Sons, L.L.C.$1K
  • BD$1K
  • Sobi, Inc$117
$379,254in research payments, 2019–2025

Across 1 payment — averaging $379,254 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astellas Pharma Inc$379K

What the payments were for

  • Consulting fees$50,35898%
  • Travel & lodging$1,1152%
  • Food & beverage$1170%

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Grifols, S.A.1$49,093
E.r. Squibb & Sons, L.L.C.1$1,265
BD1$1,115
Sobi, Inc1$117

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few blood banking & transfusion medicine providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$25,367
Medicare patients
313
Services billed
414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other blood banking & transfusion medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →